TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cutia Therapeutics ( (HK:2487) ) has issued an update.
Cutia Therapeutics has successfully completed the placement of 28,904,000 new shares under a general mandate, raising approximately HK$240.27 million in net proceeds. The funds will be used to advance the company’s research and development pipeline, particularly in areas such as localized adipose accumulation management and skin diseases, as well as to deploy necessary production facilities and equipment.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics is a company incorporated in the Cayman Islands, focusing on healthcare solutions. Its primary products and services include pre-clinical research and development, and clinical trials for localized adipose accumulation management, scalp diseases and care, skin diseases and care, and topical anesthesia.
Average Trading Volume: 1,216,890
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$3.18B
See more data about 2487 stock on TipRanks’ Stock Analysis page.